CN107198681A - 一种吲哚美辛水凝胶贴剂 - Google Patents
一种吲哚美辛水凝胶贴剂 Download PDFInfo
- Publication number
- CN107198681A CN107198681A CN201710343779.0A CN201710343779A CN107198681A CN 107198681 A CN107198681 A CN 107198681A CN 201710343779 A CN201710343779 A CN 201710343779A CN 107198681 A CN107198681 A CN 107198681A
- Authority
- CN
- China
- Prior art keywords
- indomethacin
- oil
- phase component
- hydrogel patch
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 title claims abstract description 73
- 229960000905 indomethacin Drugs 0.000 title claims abstract description 36
- 239000000017 hydrogel Substances 0.000 title claims abstract description 27
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000004471 Glycine Substances 0.000 claims abstract description 10
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical class CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 8
- -1 glyceryl laurate ester Chemical class 0.000 claims abstract description 8
- 239000000945 filler Substances 0.000 claims abstract description 6
- 239000011241 protective layer Substances 0.000 claims abstract description 6
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims abstract description 5
- 229940074046 glyceryl laurate Drugs 0.000 claims abstract description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229940070765 laurate Drugs 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 239000003002 pH adjusting agent Substances 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000011187 glycerol Nutrition 0.000 claims abstract description 4
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims abstract description 4
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims abstract description 4
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 claims abstract description 3
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 claims abstract description 3
- UTUUIUQHGDRVPU-UHFFFAOYSA-K aluminum;2-aminoacetate;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Al+3].NCC([O-])=O UTUUIUQHGDRVPU-UHFFFAOYSA-K 0.000 claims abstract description 3
- 229940082484 carbomer-934 Drugs 0.000 claims abstract description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000005995 Aluminium silicate Substances 0.000 claims description 3
- 235000012211 aluminium silicate Nutrition 0.000 claims description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical group O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 10
- 238000000034 method Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012738 dissolution medium Substances 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000700159 Rattus Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000003578 releasing effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical group CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000010643 fennel seed oil Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
一种吲哚美辛水凝胶贴剂，由背衬层、药物储库和保护层组成，其特征是所述药物储库由以下重量百分比的组分组成：作为活性成分的吲哚美辛0.3～0.5％；油相成分5～10％，所述油相成分由1:0.05～0.06的月桂酸甘油酯和和月桂酸组成，所述吲哚美辛分散于油相中；作为水相成分的部分中和聚丙烯酸钠5‑10％，丙三醇15‑20％，卡波姆934 1％～1.5％、羟丙基甲基纤维素(HPMC)1.5～2％，pH调节剂、甘羟铝0.2％～0.4％，依地酸钙钠0.1％～0.3％，L‑甘氨酸0.3％～0.5％，N‑乙酰半胱氨酸(NAC)0.5～1％，填充剂1～3％及余量的水。
Description
技术领域
本发明涉及一种吲哚美辛水凝胶贴剂。
背景技术
吲哚美辛(2-甲基-1-(4-氯苯甲酰基)-5-甲氧基-1H-吲哚-3-乙酸,CAS:53-86-1)是一种非甾体抗炎药，具有解热、镇痛作用，广泛应用于骨关节炎、风湿类风湿关节炎的镇痛治疗。但传统的口服给药方式在治疗外伤及关节、软组织、肌肉的炎症产生的疼痛时，因需要服药量较大，造成副作用较大，且无法控制药物释放，难于对患处进行持久有效的镇痛消炎效果。与常规外用制剂相比，水凝胶贴剂(巴布剂，Cataplasm)具有载药量大，促进药物经皮透过，且对皮肤无过敏反应和刺激作用，剥离时无拉痛感且无残留等优点。现有市售的一种吲哚美辛水凝胶贴剂产品，如日本尼普洛外用药品株式会社的吲哚美辛巴布膏，其规格为45.5mg/13g及13g膏体/140cm2。其采用的辅料为克罗米通、N-甲基-2-吡咯烷酮、薄荷油、聚丙烯酸酯、羧乙烯聚合物、甲基纤维素钠、明胶、氢氧化铝凝胶、蓖麻油60、聚山梨醇酯、聚丁烯、丙二醇、浓缩甘油、液体石蜡、酒石酸、依地酸二钠、茴香油、无水硅酸、氧化钛。现有技术文献——Viscomate NP-800基吲哚美辛水凝胶贴剂的研究(许建朝等，现代生物医学进展，2010年12月，4356～4359)指出了加入薄荷脑及氮酮的水凝胶贴剂配方能够表现出较好的皮肤透过性。然而由于水凝胶贴剂的药物储库中载药量较大，且一般需要敷贴较长时间，其理想的释药特性应该是快速持续释放，在快速起效的同时在整个敷贴周期内都能持续稳定的释药，而现有的吲哚美辛巴布剂无法满足上述性能要求，因此提供一种能够快速持续释药的吲哚美辛水凝胶贴剂成为现有技术中亟待解决的问题。
发明内容
为解决前述技术问题，本发明提供了一种吲哚美辛水凝胶贴剂，所述水凝胶贴剂由背衬层、药物储库和保护层组成，其特征是所述药物储库由以下重量百分比的组分组成：
作为活性成分的吲哚美辛0.3～0.5％；
油相成分5～10％，所述油相成分由1:0.05～0.06的月桂酸甘油酯和和月桂酸组成，所述吲哚美辛分散于油相中；
作为水相成分的部分中和聚丙烯酸钠5-10％，丙三醇15-20％，卡波姆934 1％～1.5％、羟丙基甲基纤维素(HPMC)1.5～2％，pH调节剂、甘羟铝0.2％～0.4％，依地酸钙钠0.1％～0.3％，L-甘氨酸0.3％～0.5％，N-乙酰半胱氨酸(NAC)0.5～1％，填充剂1～3％及余量的水；所述部分中和聚乙烯酸钠优选为NP700。所述pH调节剂为将水相成分pH调节至5～6.5的氢氧化钠溶液。所述填充剂为高岭土。
在研究中发现，将吲哚美辛溶解在油相成分后再乳化分散于水凝胶中形成药物储库，既可以持续快速释药，又可以控制释药速度，从而显著提高水凝胶贴剂中作为活性成分的吲哚美辛的透皮吸收速度，能够实现有效成分的快速和持续稳定释放。且在研究中我们进一步发现，该效果依赖于油相成分的组成配比及水相成分中特定比例N-乙酰半胱氨酸与甘氨酸的加入，油相成分经过筛选采用了加入了少量月桂酸的月桂酸甘油酯，改变油相成分的成分及配比均会显著影响吲哚美辛的释放速度，，而水相成分中的特定比例的N-乙酰半胱氨酸与甘氨酸则可以使水凝胶贴剂在敷贴后期也保持较高的释放速度。三者匹配，使得到的吲哚美辛水凝胶贴剂能够兼顾快速与持续释药性能。在处方筛选时我们进一步发现，N-乙酰半胱氨酸与甘氨酸的选取与比例确定具有特定性，无论是减少其中任何一种成分，或者改变其用量，均会显著影响到的水凝胶贴剂的释药性能，且上述处方仅在活性成分为吲哚美辛时效果明显，改变活性成分时，其释药性能明显低于本发明提供的吲哚美辛水凝胶贴剂。
具体实施方式
本发明实施例中的一种吲哚美辛水凝胶贴剂按照以下方法制备
1)油相成分配制，将油相成分的原料加热至50-70℃，加入吲哚美辛微粉，搅拌分散得到油相液(1)
2)将水相成分散于水得到水凝胶，将水凝胶加热至50～70℃后在用均混器搅拌的同时加入温度为50-70℃的油相液(1)，油相加入后再加入填充剂后搅拌均匀；经静置真空脱气后得到膏状的药物储库；
3)将药物储库涂布于背衬层上，并在上表面贴附保护层。得到吲哚美辛巴布贴。得到的一种吲哚美辛水凝胶贴剂的规格为3g药物储库/34cm2背衬层
所有实施例及对照例中，部分中和聚丙烯酸钠为NP700(Showa Denko kk生产)，填充剂为2％高岭土。
实施例1～6的配方见下表
对照例1～6的配方见下表
与实施例1～6相比，对照例1～6的配方中部分不加入月桂酸或加入更多月桂酸(对照例1、2)，部分不加入NAC或L-甘氨酸(对照例3、4)，部分改变NAC与L-甘氨酸的比例(对照例5、6)
通过对实施例1～6得到的巴布剂进行考察，可知其外观平整、均匀，药物储库膏体光滑；成型性、含膏量、初粘力、粘附性以及膜残留量均符合要求。
药理实施例1体外释放实验
按照中国药典2010版第二部附录XD中释放度测定法中第三法(桨碟法，用于透皮贴剂)中提供的方法对实施例1～6得到的巴布贴紧急释放度测定。具体方法如下
试验以生理盐水为释放介质，将释放介质加入溶出杯内，预温至(32±0.5℃)将巴布剂除去保护层，裁剪成2.5cmx7.5cm大小，平放入透析袋(截留分子量14,000)中，释放面朝上,置于两层碟片之间，使碟片边缘夹住透析袋两端，再用皮筋缠绕固定,以固定碟片。于10min、20min、30min、45min、60min、90min、2h、2.5h、3h和4h分别从溶出杯内取样6mL，并补充等体积(32+0.5)℃新鲜释放介质，平行试验6片，取平均值计算。经过检测表明，本申请实施例中的巴布剂的体外释放度均在2h达到90％以上。
药理实施例2，体外透皮实验
采用改良Franz扩散池法，以离体3月龄大鼠腹部皮肤为屏障，用实施例1～6及对照例1～6制备得到的巴布贴剂进行进行体外透皮试验。具体实验方法为：
取3月龄健康大鼠麻醉处死后，用剪刀除尽腹部毛，取下无损伤的皮肤，除去皮下组织，洗净后分别固定于Franz扩散池的释放口，接受室中加入pH7.4磷酸缓冲液作释放介质，保持内皮层与溶液密切接触。将揭去保护层的巴布剂贴于皮肤上，调节水浴使外层套层温度恒定于(32±0.5)℃，搅拌速度为100rpm，分别于0、1h、2h、4h、6h、8h、12h小时吸取释放介质4ml，同时补加等量PBS液。计算累计吸收百分数(即累计透过的吲哚美辛占药物储库中吲哚美辛总量的百分比分数)结果如下表
上述结果表明，本发明提供的一种吲哚美辛水凝胶贴剂，在进行体外透皮吸收实验时，12h的累计药物透过率均高于70％，且药物释放率随时间增加速度较为均匀、说明本发明采用的技术方案中，通过分别优选油相成分与水相成分的组成，既提高了一种吲哚美辛水凝胶贴剂的透皮吸收速度，又能够控制药物在整个敷贴时间段内较为均匀的释放，实现了两种特性的平衡。在处方筛选时我们发现油相成分优选月桂酸甘油酯与月桂酸的组合，水相成分优选NAC与L-甘氨酸的组合，仅有同时具备处方范围内的上述成分，才能实现吲哚美辛快速均匀释放的效果。通过与对比例的对照实验表明，不加入或过量加入月桂酸，仅加入NAC或L-甘氨酸中的一种或者改变两者配比，均会影响的吲哚美辛释放效果，且在进一步实验中我们还发现，该辅料配方与吲哚美辛均有关联性，当改变活性成分时，即使采用同样的辅料配方，也会无法产生本发明提供的一种吲哚美辛水凝胶贴剂具有的快速均匀释药效果。
Claims (2)
1.一种吲哚美辛水凝胶贴剂，所述水凝胶贴剂由背衬层、药物储库和保护层组成，其特征是所述药物储库由以下重量百分比的组分组成：作为活性成分的吲哚美辛0.3～0.5％；
油相成分5～10％，所述油相成分由1:0.05～0.06的月桂酸甘油酯和和月桂酸组成，所述吲哚美辛分散于油相中；
作为水相成分的部分中和聚丙烯酸钠5-10％，丙三醇15-20％，卡波姆934 1％～1.5％、羟丙基甲基纤维素1.5～2％，pH调节剂、甘羟铝0.2％～0.4％，依地酸钙钠0.1％～0.3％，L-甘氨酸0.3％～0.5％，N-乙酰半胱氨酸0.5～1％，填充剂1～3％及余量的水；所述部分中和聚乙烯酸钠为NP700，pH调节剂为将水相成分pH调节至5～6.5的氢氧化钠溶液。
2.如权利要求1所述的一种吲哚美辛水凝胶贴剂，其特征在于，所述填充剂为高岭土。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710343779.0A CN107198681A (zh) | 2017-05-16 | 2017-05-16 | 一种吲哚美辛水凝胶贴剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710343779.0A CN107198681A (zh) | 2017-05-16 | 2017-05-16 | 一种吲哚美辛水凝胶贴剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107198681A true CN107198681A (zh) | 2017-09-26 |
Family
ID=59905293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710343779.0A Pending CN107198681A (zh) | 2017-05-16 | 2017-05-16 | 一种吲哚美辛水凝胶贴剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107198681A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114939103A (zh) * | 2022-05-27 | 2022-08-26 | 辽宁方诺生物科技有限公司 | 吲哚美辛凝胶剂及其制备方法和应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1029542A1 (en) * | 1997-10-15 | 2000-08-23 | Taisho Pharmaceutical Co., Ltd | Percutaneously absorbable preparation |
| CN101094669A (zh) * | 2004-12-28 | 2007-12-26 | 兴和株式会社 | 含有吲哚美辛的贴剂 |
| CN104367566A (zh) * | 2013-08-12 | 2015-02-25 | 和心医药科技（上海）有限公司 | 一种吲哚美辛巴布剂及其组合物 |
| CN105287361A (zh) * | 2015-11-13 | 2016-02-03 | 北京泰德制药股份有限公司 | 含有非甾体抗炎药微乳的皮肤外用制剂 |
-
2017
- 2017-05-16 CN CN201710343779.0A patent/CN107198681A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1029542A1 (en) * | 1997-10-15 | 2000-08-23 | Taisho Pharmaceutical Co., Ltd | Percutaneously absorbable preparation |
| CN101094669A (zh) * | 2004-12-28 | 2007-12-26 | 兴和株式会社 | 含有吲哚美辛的贴剂 |
| CN104367566A (zh) * | 2013-08-12 | 2015-02-25 | 和心医药科技（上海）有限公司 | 一种吲哚美辛巴布剂及其组合物 |
| CN105287361A (zh) * | 2015-11-13 | 2016-02-03 | 北京泰德制药股份有限公司 | 含有非甾体抗炎药微乳的皮肤外用制剂 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114939103A (zh) * | 2022-05-27 | 2022-08-26 | 辽宁方诺生物科技有限公司 | 吲哚美辛凝胶剂及其制备方法和应用 |
| CN114939103B (zh) * | 2022-05-27 | 2023-11-17 | 辽宁方诺生物科技有限公司 | 吲哚美辛凝胶剂及其制备方法和应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2809307B1 (en) | Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine | |
| CN106667970B (zh) | 氟比洛芬巴布剂 | |
| JP6259454B2 (ja) | ジクロフェナク製剤 | |
| CN104188942A (zh) | 经皮吸收促进剂及其外部皮肤制剂 | |
| CN104546803A (zh) | 一种氟比洛芬水凝胶贴膏及其组合物 | |
| CN105287361B (zh) | 含有非甾体抗炎药微乳的皮肤外用制剂 | |
| CN107157962A (zh) | 氟比洛芬巴布剂 | |
| CN101530401A (zh) | 一种用于治疗急慢性炎性疼痛的复方透皮贴片 | |
| NO338478B1 (no) | Utvortes plaster inneholdende etofenamat | |
| CN106822065A (zh) | 一种氟比洛芬巴布剂 | |
| JP2009173679A (ja) | 部分的ドーパミン−ｄ２作用薬の投与用の経皮治療吸収システム | |
| CN102370631A (zh) | 一种治疗痛经的皮肤外用贴剂 | |
| JPH04266818A (ja) | 医療用粘着剤 | |
| JP5900971B2 (ja) | 経皮吸収促進剤及びそれを含有する経皮吸収型製剤 | |
| JPH0662401B2 (ja) | ケトプロフエン含有パツプ剤 | |
| CN107198681A (zh) | 一种吲哚美辛水凝胶贴剂 | |
| US4826686A (en) | Therapeutic system | |
| PT88440B (pt) | Processo para a preparacao de emplastros contendo salbutamol | |
| CN102772417B (zh) | 包载睾酮的自黏性弹性体基质的周效经皮贴剂及制法 | |
| ES2226836T3 (es) | Dispositivo transdermico para la administracion de testorona o de uno de sus derivados. | |
| CN101612141B (zh) | 丁丙诺啡贴剂 | |
| WO2012090322A1 (ja) | 貼付剤 | |
| CN112826809A (zh) | 一种稳定的妥洛特罗经皮吸收制剂 | |
| CN107951864A (zh) | 氟比洛芬巴布剂 | |
| CN107028921A (zh) | 一种吡罗昔康巴布贴剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190522 Address after: 102629 Second Floor and Third Floor of Building 12, No. 50 Huatuo Road, Daxing Biomedical Base, Beijing (Liandong U Valley Biomedical Science and Technology Park) Applicant after: BEIJING MINGZE ZHONGHE MEDICAMENT RESEARCH CO., LTD. Address before: 528139 No. 20, Dushugang New Village Team, Lubao Town, Sanshui District, Foshan City, Guangdong Province Applicant before: Cai Zhihao |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170926 |
|
| RJ01 | Rejection of invention patent application after publication |